| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Academic diversity programmes for non-US international medical graduates
|
Villamar, Mauricio F
|
|
|
|
2 |
p. 115
|
artikel
|
| 2 |
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|
Cooke, Graham S
|
|
2019
|
|
2 |
p. 135-184
|
artikel
|
| 3 |
Accelerating the elimination of viral hepatitis for Indigenous peoples
|
Cunningham, Chris
|
|
2019
|
|
2 |
p. 93-94
|
artikel
|
| 4 |
An Australian perspective on monkeypox virus and stool transplants
|
Koh, Bryant
|
|
|
|
2 |
p. 114-115
|
artikel
|
| 5 |
An open letter to Gavi: hepatitis B birth dose vaccine can't wait
|
|
|
|
|
2 |
p. 115-116
|
artikel
|
| 6 |
Another arrow in the NASH quiver?
|
Forlano, Roberta
|
|
|
|
2 |
p. 96-97
|
artikel
|
| 7 |
An unusual complication after a variceal glue injection
|
Morgan, James A
|
|
|
|
2 |
p. 198
|
artikel
|
| 8 |
A plea for TDM-based optimisation for treatment of Crohn's disease
|
Seinen, Margien L
|
|
|
|
2 |
p. 81
|
artikel
|
| 9 |
A plea for TDM-based optimisation for treatment of Crohn's disease – Authors' reply
|
Kennedy, Nicholas A
|
|
|
|
2 |
p. 81-82
|
artikel
|
| 10 |
A specific link between migraine and functional GI disorders
|
Palsson, Olafur S
|
|
2016
|
|
2 |
p. 89-90
2 p.
|
artikel
|
| 11 |
Association between functional gastrointestinal disorders and migraine in children and adolescents: a case-control study
|
Le Gal, Julie
|
|
2016
|
|
2 |
p. 114-121
8 p.
|
artikel
|
| 12 |
Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models
|
DiMartini, Andrea F
|
|
|
|
2 |
p. 186-195
|
artikel
|
| 13 |
Boiling Point
|
Bisbas, Georgia
|
|
|
|
2 |
p. 109
|
artikel
|
| 14 |
Bringing transplantation to life
|
Zajanckauskaite, Estera
|
|
|
|
2 |
p. 84
|
artikel
|
| 15 |
Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium
|
Yang, Ju Dong
|
|
|
|
2 |
p. 103-111
|
artikel
|
| 16 |
Chronic hepatitis B: identifying who needs to be treated and improving linkage to care
|
Spearman, C Wendy
|
|
|
|
2 |
p. 83-85
|
artikel
|
| 17 |
Civil society's critical role in the elimination of viral hepatitis
|
Peck, Raquel
|
|
2019
|
|
2 |
p. 90-91
|
artikel
|
| 18 |
Communities living with hepatitis must be central to the response to liver diseases in the Asia-Pacific region
|
Wingrove, Chris
|
|
|
|
2 |
p. 107-109
|
artikel
|
| 19 |
Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis
|
Facciorusso, Antonio
|
|
|
|
2 |
p. 94-102
|
artikel
|
| 20 |
Continuous wound infiltration versus epidural analgesia after hepato-pancreato-biliary surgery (POP-UP): a randomised controlled, open-label, non-inferiority trial
|
Mungroop, Timothy H
|
|
2016
|
|
2 |
p. 105-113
9 p.
|
artikel
|
| 21 |
Core inhibitor therapy for chronic hepatitis B
|
Sonneveld, Milan J
|
|
|
|
2 |
p. 99-100
|
artikel
|
| 22 |
Correction to Lancet Gastroenterol Hepatol 2023; 8: 81–94
|
|
|
|
|
2 |
p. 117
|
artikel
|
| 23 |
Correction to Lancet Gastroenterol Hepatol 2018; 3: 825–36
|
|
|
2019
|
|
2 |
p. e1
|
artikel
|
| 24 |
Correction to Lancet Gastroenterol Hepatol 2019; 4: 454–65
|
|
|
|
|
2 |
p. e1
|
artikel
|
| 25 |
Correction to Lancet Gastroenterol Hepatol 2019; 4: 907–08
|
|
|
|
|
2 |
p. e1
|
artikel
|
| 26 |
Correction to Lancet Gastroenterol Hepatol 2022; 7: 152–60
|
|
|
|
|
2 |
p. e2
|
artikel
|
| 27 |
Correction to Lancet Gastroenterol Hepatol 2020; 5: 1039–52
|
|
|
|
|
2 |
p. e1
|
artikel
|
| 28 |
Correction to Lancet Gastroenterol Hepatol 2021; 6: 106–19
|
|
|
|
|
2 |
p. e1
|
artikel
|
| 29 |
Correction to Lancet Gastroenterol Hepatol 2023; 8: 908–18
|
|
|
|
|
2 |
p. e2
|
artikel
|
| 30 |
Diagnostic accuracy of MRE and ultrasound for Crohn's disease
|
Novak, Kerri
|
|
2019
|
|
2 |
p. 95-96
|
artikel
|
| 31 |
Diagnostic accuracy of MRE and ultrasound for Crohn's disease – Authors' reply
|
Taylor, Stuart A
|
|
2019
|
|
2 |
p. 96
|
artikel
|
| 32 |
Digging deeper into alcohol-related deaths
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
2 |
p. 107
|
artikel
|
| 33 |
Direct-acting antiviral therapy in sub-Saharan Africa
|
Spearman, C Wendy
|
|
2019
|
|
2 |
p. 85-86
|
artikel
|
| 34 |
Direct oral anticoagulants and gastroenterologists
|
Sugano, Kentaro
|
|
|
|
2 |
p. 74-75
|
artikel
|
| 35 |
Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease
|
Degasperi, Elisabetta
|
|
2016
|
|
2 |
p. 156-164
9 p.
|
artikel
|
| 36 |
Effective drugs on the road to HCV elimination and a therapeutic gap to close
|
Muljono, David H
|
|
2019
|
|
2 |
p. 86-88
|
artikel
|
| 37 |
Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial
|
Miller, Eric A
|
|
2019
|
|
2 |
p. 101-110
|
artikel
|
| 38 |
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial
|
Gupta, Sunil
|
|
|
|
2 |
p. 152-160
|
artikel
|
| 39 |
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
|
Lasa, Juan S
|
|
|
|
2 |
p. 161-170
|
artikel
|
| 40 |
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
|
Lau, George
|
|
2016
|
|
2 |
p. 97-104
8 p.
|
artikel
|
| 41 |
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
|
Danese, Silvio
|
|
|
|
2 |
p. 133-146
|
artikel
|
| 42 |
Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis
|
Black, Christopher J
|
|
|
|
2 |
p. 117-131
|
artikel
|
| 43 |
Elastosis perforans serpiginosa in a patient with Wilson's disease
|
Thwaites, Phoebe A
|
|
|
|
2 |
p. 144
|
artikel
|
| 44 |
Elimination of viral hepatitis by 2030: ambitious, but achievable
|
Brierley, Rob
|
|
2019
|
|
2 |
p. 88-89
|
artikel
|
| 45 |
Endoscopic ultrasonography-guided gastroenterostomy: the end of the duodenal stent?
|
Lekkerkerker, Selma J
|
|
|
|
2 |
p. 95-97
|
artikel
|
| 46 |
Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial
|
Teoh, Anthony Yuen Bun
|
|
|
|
2 |
p. 124-132
|
artikel
|
| 47 |
Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis
|
Tan, Mingjuan
|
|
|
|
2 |
p. 106-119
|
artikel
|
| 48 |
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
|
Peyrin-Biroulet, Laurent
|
|
|
|
2 |
p. 128-140
|
artikel
|
| 49 |
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
|
Danese, Silvio
|
|
|
|
2 |
p. 118-127
|
artikel
|
| 50 |
Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial
|
Yang, Han Kwang
|
|
|
|
2 |
p. 120-127
|
artikel
|
| 51 |
Faecal immunochemical tests: when quantitation is not enough
|
Halloran, Stephen P
|
|
2019
|
|
2 |
p. 83-84
|
artikel
|
| 52 |
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection
|
Krutova, Marcela
|
|
|
|
2 |
p. 111-112
|
artikel
|
| 53 |
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection
|
van Prehn, Joffrey
|
|
|
|
2 |
p. 109
|
artikel
|
| 54 |
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection
|
Goldenberg, Simon D
|
|
|
|
2 |
p. 109-110
|
artikel
|
| 55 |
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection
|
Aby, Elizabeth S
|
|
|
|
2 |
p. 110-111
|
artikel
|
| 56 |
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection – Authors' reply
|
Baunwall, Simon Mark Dahl
|
|
|
|
2 |
p. 112-113
|
artikel
|
| 57 |
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative
|
Verma, Ajay M
|
|
|
|
2 |
p. 88-89
|
artikel
|
| 58 |
Gluten: going against the grain?
|
The Lancet Gastroenterology & Hepatology,
|
|
2016
|
|
2 |
p. 85-
1 p.
|
artikel
|
| 59 |
Guselkumab in Crohn's disease: the IL-23 race continues
|
Fumery, Mathurin
|
|
|
|
2 |
p. 97-98
|
artikel
|
| 60 |
Headway and hurdles in non-alcoholic fatty liver disease
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
2 |
p. 93
|
artikel
|
| 61 |
Hepatitis C: individualised medicine versus one pill fits all
|
Cornberg, Markus
|
|
2016
|
|
2 |
p. 86-87
2 p.
|
artikel
|
| 62 |
Hepatitis C treatment and liver cancer recurrence: cause for concern?
|
Debes, Jose D
|
|
|
|
2 |
p. 78-80
|
artikel
|
| 63 |
Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
|
Thomas, James A
|
|
|
|
2 |
p. 159-169
|
artikel
|
| 64 |
High-dose NSAIDs and pancreatitis after ERCP: more is not always better
|
Rana, Surinder Singh
|
|
|
|
2 |
p. 95-97
|
artikel
|
| 65 |
How many deaths are caused by non-alcoholic fatty liver disease in the Asia-Pacific region?
|
Wong, Grace Lai-Hung
|
|
|
|
2 |
p. 103-105
|
artikel
|
| 66 |
Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas
|
Hamid, Saeed
|
|
|
|
2 |
p. 89-90
|
artikel
|
| 67 |
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial
|
Ghaneh, Paula
|
|
|
|
2 |
p. 157-168
|
artikel
|
| 68 |
Inflammatory bowel disease health care for LGTBQIA+ patients
|
Dibley, Lesley
|
|
|
|
2 |
p. 100-101
|
artikel
|
| 69 |
Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities
|
Ma, Christopher
|
|
|
|
2 |
p. 110-112
|
artikel
|
| 70 |
Intrarectal injections of botulinum toxin versus placebo for the treatment of urge faecal incontinence in adults (FI-Toxin): a double-blind, multicentre, randomised, controlled phase 3 study
|
Leroi, Anne-Marie
|
|
|
|
2 |
p. 147-158
|
artikel
|
| 71 |
Is dilution the solution in gastric cancer?
|
Hundeyin, Mautin
|
|
|
|
2 |
p. 85-86
|
artikel
|
| 72 |
Lessons and open questions in borderline resectable pancreatic cancer
|
Reni, Michele
|
|
|
|
2 |
p. 101-102
|
artikel
|
| 73 |
LGBTQIA+ affirming palliative care and communication in liver transplantation
|
Rosa, William E
|
|
|
|
2 |
p. 106-107
|
artikel
|
| 74 |
Liver cancer in Africa: untold aspects of an acknowledged scourge
|
Ojo, Olusegun Sylvester
|
|
|
|
2 |
p. 76-77
|
artikel
|
| 75 |
Liver disease in Canada: the scale of the problem
|
Burki, Talha K
|
|
|
|
2 |
p. 114-115
|
artikel
|
| 76 |
Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission
|
Sarin, Shiv K
|
|
|
|
2 |
p. 167-228
|
artikel
|
| 77 |
Living
|
Barker, George
|
|
|
|
2 |
p. 119
|
artikel
|
| 78 |
Living with an inflammatory bowel disease
|
Old, Robert
|
|
2016
|
|
2 |
p. 96-
1 p.
|
artikel
|
| 79 |
Local and systemic therapy in liver cancer: the quest for synergy
|
Pinter, Matthias
|
|
|
|
2 |
p. 102-104
|
artikel
|
| 80 |
Low intensity treatment in metastatic colorectal cancer
|
Wong, Hui-Li
|
|
|
|
2 |
p. 97-99
|
artikel
|
| 81 |
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial
|
Haifer, Craig
|
|
|
|
2 |
p. 141-151
|
artikel
|
| 82 |
Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial
|
Sivarajan, Sri
|
|
|
|
2 |
p. 102
|
artikel
|
| 83 |
Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial
|
Bir Yücel, Kadriye
|
|
|
|
2 |
p. 102-103
|
artikel
|
| 84 |
Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial
|
Weijs, Teus J
|
|
|
|
2 |
p. 103-104
|
artikel
|
| 85 |
Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial – Authors' reply
|
Reynolds, John V
|
|
|
|
2 |
p. 104-105
|
artikel
|
| 86 |
Management of the multiple symptoms of irritable bowel syndrome
|
Simrén, Magnus
|
|
|
|
2 |
p. 112-122
|
artikel
|
| 87 |
Managing cirrhosis with limited resources: perspectives from sub-Saharan Africa
|
Sonderup, Mark W
|
|
|
|
2 |
p. 170-184
|
artikel
|
| 88 |
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
|
Targher, Giovanni
|
|
|
|
2 |
p. 179-191
|
artikel
|
| 89 |
Minimally invasive gastrectomy: time to change practice?
|
Berlth, Felix
|
|
|
|
2 |
p. 97-98
|
artikel
|
| 90 |
Modifying Rome IV for clinical practice
|
Burki, Talha Khan
|
|
|
|
2 |
p. 116
|
artikel
|
| 91 |
Molecular endoscopy for targeted imaging in the digestive tract
|
Lee, Jeong Hoon
|
|
2016
|
|
2 |
p. 147-155
9 p.
|
artikel
|
| 92 |
Moving forward with organ preservation in rectal cancer
|
Beets, Geerard L
|
|
|
|
2 |
p. 82-83
|
artikel
|
| 93 |
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
|
Kunzmann, Volker
|
|
|
|
2 |
p. 128-138
|
artikel
|
| 94 |
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
|
Liu, Zhigang
|
|
|
|
2 |
p. 145-156
|
artikel
|
| 95 |
New hepatitis B drug development disillusions: time to reset?
|
Pawlotsky, Jean-Michel
|
|
|
|
2 |
p. 192-197
|
artikel
|
| 96 |
Non-coeliac gluten sensitivity: from Salerno to Rome
|
Shiha, Mohamed G
|
|
|
|
2 |
p. 94-95
|
artikel
|
| 97 |
Optimum timing of treatment for hepatitis C infection relative to liver transplantation
|
Coilly, Audrey
|
|
2016
|
|
2 |
p. 165-172
8 p.
|
artikel
|
| 98 |
Oral lyophilised microbiota for the treatment of ulcerative colitis
|
Fischer, Monika
|
|
|
|
2 |
p. 108-109
|
artikel
|
| 99 |
Palliative care in advanced liver disease: time for action
|
Verma, Sumita
|
|
|
|
2 |
p. 106-108
|
artikel
|
| 100 |
Pancreatic cancer: a state of emergency?
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
2 |
p. 81
|
artikel
|
| 101 |
Pancreatic cancer: how can we tackle the lack of progress?
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
2 |
p. 73
|
artikel
|
| 102 |
Parsimony prevails: Botulinum toxin and the overactive rectum
|
Knowles, Charles H
|
|
|
|
2 |
p. 98-100
|
artikel
|
| 103 |
Pathophysiology of irritable bowel syndrome
|
Holtmann, Gerald J
|
|
2016
|
|
2 |
p. 133-146
14 p.
|
artikel
|
| 104 |
Patient experience in HCV therapy: what really matters
|
Buti, María
|
|
2016
|
|
2 |
p. 90-92
3 p.
|
artikel
|
| 105 |
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial
|
Younossi, Zobair M
|
|
2016
|
|
2 |
p. 122-132
11 p.
|
artikel
|
| 106 |
Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme
|
de Klerk, Clasine M
|
|
2019
|
|
2 |
p. 111-118
|
artikel
|
| 107 |
Perioperative analgesia in hepato-pancreato-biliary surgery
|
Wigmore, Stephen J
|
|
2016
|
|
2 |
p. 87-89
3 p.
|
artikel
|
| 108 |
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia
|
Zhang, Fei
|
|
|
|
2 |
p. 113-114
|
artikel
|
| 109 |
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply
|
Kuipers, Thijs
|
|
|
|
2 |
p. 114
|
artikel
|
| 110 |
Polyethylene glycol-based laxatives for chronic constipation
|
Akriche, Fatma
|
|
|
|
2 |
p. 110
|
artikel
|
| 111 |
Polyethylene glycol-based laxatives for chronic constipation – Authors' reply
|
Luthra, Pavit
|
|
|
|
2 |
p. 110-111
|
artikel
|
| 112 |
Prevention of bleeding after EMR of colorectal lesions: when and how?
|
Mohapatra, Sonmoon
|
|
|
|
2 |
p. 109-110
|
artikel
|
| 113 |
Probiotics: elixir or empty promise?
|
The Lancet Gastroenterology & Hepatology,
|
|
2019
|
|
2 |
p. 81
|
artikel
|
| 114 |
Project ECHO: democratising knowledge for the elimination of viral hepatitis
|
Arora, Sanjeev
|
|
2019
|
|
2 |
p. 91-93
|
artikel
|
| 115 |
Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study
|
Bach, Simon P
|
|
|
|
2 |
p. 92-105
|
artikel
|
| 116 |
Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial
|
Fogel, Evan L
|
|
|
|
2 |
p. 132-141
|
artikel
|
| 117 |
Research in brief
|
Baker, Holly
|
|
|
|
2 |
p. 83
|
artikel
|
| 118 |
Research in Brief
|
Baker, Holly
|
|
|
|
2 |
p. 118
|
artikel
|
| 119 |
Research in brief
|
Baker, Holly
|
|
2016
|
|
2 |
p. 93-
1 p.
|
artikel
|
| 120 |
Research in brief
|
Baker, Holly
|
|
2019
|
|
2 |
p. 99
|
artikel
|
| 121 |
Research in Brief
|
Baker, Holly
|
|
|
|
2 |
p. 113
|
artikel
|
| 122 |
Research in Brief
|
Baker, Holly
|
|
|
|
2 |
p. 117
|
artikel
|
| 123 |
Research in brief
|
Baker, Holly
|
|
|
|
2 |
p. 91
|
artikel
|
| 124 |
Research in Brief
|
Baker, Holly
|
|
|
|
2 |
p. 108
|
artikel
|
| 125 |
Restricting alcohol consumption to reduce liver disease in the Asia-Pacific region
|
Jiang, Heng
|
|
|
|
2 |
p. 105-107
|
artikel
|
| 126 |
Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis
|
Burr, Nick
|
|
|
|
2 |
p. 85-93
|
artikel
|
| 127 |
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B
|
Choi, Won-Mook
|
|
|
|
2 |
p. 87
|
artikel
|
| 128 |
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B – Authors' reply
|
Tseng, Cheng-Hao
|
|
|
|
2 |
p. 87-88
|
artikel
|
| 129 |
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
|
Yuen, Man-Fung
|
|
|
|
2 |
p. 152-166
|
artikel
|
| 130 |
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
|
Loomba, Rohit
|
|
|
|
2 |
p. 120-132
|
artikel
|
| 131 |
Samuel Gee: the modern era for coeliac disease
|
Burki, Talha Khan
|
|
2019
|
|
2 |
p. 100
|
artikel
|
| 132 |
Septic arthritis: a presentation of Crohn's disease
|
Özpolat, Hasan Tahsin
|
|
|
|
2 |
p. 196
|
artikel
|
| 133 |
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial
|
Chiang, Chi Leung
|
|
|
|
2 |
p. 169-178
|
artikel
|
| 134 |
Sigmoidoscopy: a shortcut to effective screening or a dead end?
|
Bugajski, Marek
|
|
2019
|
|
2 |
p. 82-83
|
artikel
|
| 135 |
Significance of anti-HBc alone serological status in clinical practice
|
Wang, Qixia
|
|
|
|
2 |
p. 123-134
|
artikel
|
| 136 |
Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
|
Wei, Lai
|
|
2019
|
|
2 |
p. 127-134
|
artikel
|
| 137 |
Soul survivor
|
van Dorn, Aaron
|
|
2016
|
|
2 |
p. 96-
1 p.
|
artikel
|
| 138 |
Successful control of ulcerative colitis
|
Hastings, Barbara
|
|
|
|
2 |
p. 116
|
artikel
|
| 139 |
Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial
|
Katai, Hitoshi
|
|
|
|
2 |
p. 142-151
|
artikel
|
| 140 |
Sustain, accelerate, innovate: the burden of liver disease and way forward in the WHO South-East Asia region
|
Singh, Poonam Khetrapal
|
|
|
|
2 |
p. 100-102
|
artikel
|
| 141 |
Tackling the burden of digestive disorders in Europe
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
2 |
p. 95
|
artikel
|
| 142 |
Terlipressin for hepatorenal syndrome: opportunities and challenges
|
Singal, Ashwani K
|
|
|
|
2 |
p. 104-106
|
artikel
|
| 143 |
Terlipressin for hepatorenal syndrome: ready for prime time
|
Ginès, Pere
|
|
|
|
2 |
p. 75-76
|
artikel
|
| 144 |
The curious case of inflammatory bowel disease
|
Mohammadi, Dara
|
|
2016
|
|
2 |
p. 94-
1 p.
|
artikel
|
| 145 |
The effect of expectancy versus actual gluten intake on gastrointestinal and extra-intestinal symptoms in non-coeliac gluten sensitivity: a randomised, double-blind, placebo-controlled, international, multicentre study
|
de Graaf, Marlijne C G
|
|
|
|
2 |
p. 110-123
|
artikel
|
| 146 |
The growth of faecal microbiota transplantation in the UK: time for a registry?
|
Inglis, David
|
|
|
|
2 |
p. 112-114
|
artikel
|
| 147 |
The Liver Meeting 2018
|
Van Epps, Heather
|
|
2019
|
|
2 |
p. 98
|
artikel
|
| 148 |
The Liver Meeting 2019
|
Feetham, Laura
|
|
|
|
2 |
p. 112
|
artikel
|
| 149 |
The overlap between irritable bowel syndrome and organic gastrointestinal diseases
|
Aziz, Imran
|
|
|
|
2 |
p. 139-148
|
artikel
|
| 150 |
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
|
Papamichael, Konstantinos
|
|
|
|
2 |
p. 171-185
|
artikel
|
| 151 |
The role of the gut microbiota in sepsis
|
Haak, Bastiaan W
|
|
|
|
2 |
p. 135-143
|
artikel
|
| 152 |
Time to act to make elimination of viral hepatitis a reality
|
Kasai, Takeshi
|
|
|
|
2 |
p. 102-103
|
artikel
|
| 153 |
Traditional treatments for irritable bowel syndrome: the state of our knowledge
|
Törnblom, Hans
|
|
|
|
2 |
p. 94-95
|
artikel
|
| 154 |
Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir–sofosbuvir (SHARED): a single-arm trial
|
Gupta, Neil
|
|
2019
|
|
2 |
p. 119-126
|
artikel
|
| 155 |
Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
|
André, Thierry
|
|
|
|
2 |
p. 133-144
|
artikel
|
| 156 |
Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern?
|
Taylor, Simeon I
|
|
|
|
2 |
p. 105
|
artikel
|
| 157 |
Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern? – Authors' reply
|
Noureddin, Mazen
|
|
|
|
2 |
p. 105-106
|
artikel
|
| 158 |
Unravelling the causes of non-coeliac gluten sensitivity
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
2 |
p. 93
|
artikel
|
| 159 |
Watch-and-wait strategy in rectal cancer
|
Bujko, Krzysztof
|
|
2019
|
|
2 |
p. 96-97
|
artikel
|
| 160 |
Watch-and-wait strategy in rectal cancer – Authors' reply
|
Chadi, Sami A
|
|
2019
|
|
2 |
p. 97
|
artikel
|
| 161 |
Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD
|
Otten, Antonius T
|
|
|
|
2 |
p. 99-100
|
artikel
|
| 162 |
Zobair Younossi: pushing for the patient's perspective
|
Mitchell, Fiona
|
|
2016
|
|
2 |
p. 95-
1 p.
|
artikel
|
Tijdschrift beschrijving